Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announced today its unaudited interim results for the six months ended 31 December 2018. Highlights Financial..
Allergy Therapeutics plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, the ultra-short course subcutaneous allergy immunotherapy (AIT), continues to..
Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specialising in allergy immunology vaccines, today provided a trading update for the six months ended 31 December 2018 ahead..
Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provided an AGM trading and regulatory update ahead of its Half Year Results to..
Allergy Therapeutics Plc (LON:AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announced that Manuel Llobet, CEO, and Nick Wykeman, CFO, will attend the Jefferies Healthcare Conference in..
Allergy Therapeutics (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announced its preliminary results for the year ended 30 June 2018. Financial highlights · 6.6%..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announced today a placing and subscription of up to 40,000,000 new ordinary shares of 0.1 pence..
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis, and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provided a trading update for the year ended 30 June 2018 ahead of its Preliminary..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announced the publication of positive data in the journal Immunotherapy, demonstrating long-lasting efficacy of Pollinex..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announced positive new data on its wholly-owned modified house-dust mite subcutaneous immunotherapy1. This data will..
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (SCIT), continues to gain market share..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announced highly positive top-line results from its Grass Modified Allergen Tyrosine Absorbed (MATA) MPL Phase..
Allergy Therapeutics Plc (LON:AGY), a leading, fully-integrated commercial biotechnology company specialising in allergy vaccines, today announces that new data from a study investigating immune responses produced by microcrystalline tyrosine (MCT®)-based..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announced today its unaudited interim results for the six months ended 31 December 2017. Highlights (including..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announced that it has signed a contract with AGC Biologics (Heidelberg, Germany) to scale up..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announced that recruitment has been completed in its grass allergy Phase II study (G205), with..
Allergy Therapeutics (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite..
Growth in a tough market Allergy Therapeutics plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT),..
